News
Publications
IBT & Novo Holdings
IBT Vaccines, a Novo Holdings Repair Impact Fund Portfolio Company
Novo Holdings REPAIR Impact Fund Invests USD 12 million in Mutabilis and IBT Vaccines and provides strategic update
Copenhagen, Denmark, 06 January 2020 – Today, the Novo Holdings REPAIR Impact Fund announced a EUR 7 million investment in Mutabilis, a company developing novel antibacterials against Gram-negative infections based near Paris, France. This [...]
IBT-V02: A Multicomponent Toxoid Vaccine Protects Against Primary and Secondary Skin Infections Caused by Staphylococcus aureus
Staphylococcus aureus causes a wide range of diseases from skin infections to life threatening invasive diseases such as bacteremia, endocarditis, pneumonia, surgical site infections, and osteomyelitis. Skin infections such as furuncles, [...]
Safety and Immunogenicity of a 4-Component Toxoid-Based Staphylococcus aureus Vaccine in Rhesus Macaques
Staphylococcus aureus is a leading cause of significant morbidity and mortality and an enormous economic burden to public health worldwide. Infections caused by methicillin-resistant S. aureus (MRSA) pose a major threat as MRSA [...]